VEGFD and lymphangioleiomyomatosis: It suggested that targeting this receptor may be beneficial for the treatment of LAM, especially considering that VEGF-D is a critical serum biomarker for LAM diagnosis and for evaluating the severity of LAM and efficacy of treatment in the presence (46, 47).